{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:09:23Z","timestamp":1792069763817,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1A2C4001842"],"award-info":[{"award-number":["2020R1A2C4001842"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00198-021-06137-5","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:03:37Z","timestamp":1630548217000},"page":"367-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Serum biomarkers for bisphosphonate-related osteonecrosis of the jaw: a prospective clinical study"],"prefix":"10.1007","volume":"33","author":[{"given":"Jung-Hyun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sura","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Jong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Dong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeung-Chul","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1672-5730","authenticated-orcid":false,"given":"Jin-Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"issue":"10","key":"6137_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O\u2019Ryan F, Association American, of Oral and Maxillofacial Surgeons, (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J Oral Maxillofac Surg 72(10):1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"issue":"6","key":"6137_CR2","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.oooo.2019.02.014","volume":"127","author":"V Moraschini","year":"2019","unstructured":"Moraschini V, de Almeida DCF, Figueredo CM, Calasans-Maia MD (2019) Association between biomarkers and medication-related osteonecrosis of the jaws: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol 127(6):504\u2013515. https:\/\/doi.org\/10.1016\/j.oooo.2019.02.014","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"1","key":"6137_CR3","first-page":"5","volume":"24","author":"AL Pouso","year":"2019","unstructured":"Pouso AL, P\u00e9rez-Say\u00e1ns M, Palanca SG, Petronacci CMC, Sebasti\u00e1n JVB, Garc\u00eda AG (2019) Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: a systematic review. Med Oral Patol Oral Cir Bucal Ed Inglesa 24(1):5","journal-title":"Med Oral Patol Oral Cir Bucal Ed Inglesa"},{"issue":"2","key":"6137_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijom.2016.10.009","volume":"46","author":"KJ Dal Pra","year":"2017","unstructured":"Dal Pra KJ, Lemos CA, Okamoto R, Soubhia AM, Pellizzer EP (2017) Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review. Int J Oral Maxillofac Surg 46(2):151\u2013156. https:\/\/doi.org\/10.1016\/j.ijom.2016.10.009","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"8","key":"6137_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.adaj.2019.03.006","volume":"150","author":"ME Awad","year":"2019","unstructured":"Awad ME, Sun C, Jernigan J, Elsalanty M (2019) Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis. J Am Dent Assoc 150(8):664-675 e668. https:\/\/doi.org\/10.1016\/j.adaj.2019.03.006","journal-title":"J Am Dent Assoc"},{"issue":"11","key":"6137_CR6","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1210\/en.2005-0333","volume":"146","author":"AJ Koh","year":"2005","unstructured":"Koh AJ, Demiralp B, Neiva KG, Hooten J, Nohutcu RM, Shim H, Datta NS, Taichman RS, McCauley LK (2005) Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146(11):4584\u20134596. https:\/\/doi.org\/10.1210\/en.2005-0333","journal-title":"Endocrinology"},{"issue":"2","key":"6137_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.molmed.2004.12.004","volume":"11","author":"TJ Martin","year":"2005","unstructured":"Martin TJ, Sims NA (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11(2):76\u201381. https:\/\/doi.org\/10.1016\/j.molmed.2004.12.004","journal-title":"Trends Mol Med"},{"issue":"4","key":"6137_CR8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1359\/jbmr.070109","volume":"22","author":"MA Karsdal","year":"2007","unstructured":"Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K (2007) Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 22(4):487\u2013494. https:\/\/doi.org\/10.1359\/jbmr.070109","journal-title":"J Bone Miner Res"},{"issue":"6","key":"6137_CR9","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.tripleo.2011.04.020","volume":"112","author":"G Subramanian","year":"2011","unstructured":"Subramanian G, Cohen HV, Quek SY (2011) A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide\u2019s potential role in its resolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112(6):744\u2013753. https:\/\/doi.org\/10.1016\/j.tripleo.2011.04.020","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"2","key":"6137_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrrheum.2011.181","volume":"8","author":"IR Reid","year":"2012","unstructured":"Reid IR, Cornish J (2012) Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol 8(2):90\u201396. https:\/\/doi.org\/10.1038\/nrrheum.2011.181","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"6137_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1749-6632.2010.05770.x","volume":"1218","author":"S Cremers","year":"2011","unstructured":"Cremers S, Farooki A (2011) Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone. Ann N Y Acad Sci 1218(1):80\u201387. https:\/\/doi.org\/10.1111\/j.1749-6632.2010.05770.x","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"6137_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00198-006-0286-8","volume":"18","author":"K Henriksen","year":"2007","unstructured":"Henriksen K, Tanko LB, Qvist P, Delmas PD, Christiansen C, Karsdal MA (2007) Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 18(5):681\u2013685. https:\/\/doi.org\/10.1007\/s00198-006-0286-8","journal-title":"Osteoporos Int"},{"issue":"2","key":"6137_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0002-9440(10)62269-9","volume":"166","author":"MA Karsdal","year":"2005","unstructured":"Karsdal MA, Henriksen K, Sorensen MG et al (2005) Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166(2):467\u2013476. https:\/\/doi.org\/10.1016\/S0002-9440(10)62269-9","journal-title":"Am J Pathol"},{"issue":"2","key":"6137_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00223-007-9091-4","volume":"82","author":"JP Rissanen","year":"2008","unstructured":"Rissanen JP, Suominen MI, Peng ZQ, Halleen JM (2008) Secreted tartrate-resistant acid phosphatase 5b is a marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int 82(2):108\u2013115. https:\/\/doi.org\/10.1007\/s00223-007-9091-4","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"6137_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00223-009-9309-8","volume":"85","author":"AJ Janckila","year":"2009","unstructured":"Janckila AJ, Yam LT (2009) Biology and clinical significance of tartrate-resistant acid phosphatases: new perspectives on an old enzyme. Calcif Tissue Int 85(6):465\u2013483. https:\/\/doi.org\/10.1007\/s00223-009-9309-8","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"6137_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D","volume":"92","author":"LC Hofbauer","year":"2001","unstructured":"Hofbauer LC, Neubauer A, Heufelder AE (2001) Receptor activator of nuclear factor-\u03baB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92(3):460\u2013470","journal-title":"Cancer"},{"issue":"2","key":"6137_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/cid.12297","volume":"18","author":"JW Kim","year":"2016","unstructured":"Kim JW, Cha IH, Kim SJ, Kim MR (2016) Biomarkers for bisphosphonate-related osteonecrosis of the jaw. Clin Implant Dent Relat Res 18(2):281\u2013291. https:\/\/doi.org\/10.1111\/cid.12297","journal-title":"Clin Implant Dent Relat Res"},{"key":"6137_CR18","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.bone.2015.08.012","volume":"81","author":"JW Kim","year":"2015","unstructured":"Kim JW, Tatad JCI, Landayan MEA, Kim SJ, Kim MR (2015) Animal model for medication-related osteonecrosis of the jaw with precedent metabolic bone disease. Bone 81:442\u2013448. https:\/\/doi.org\/10.1016\/j.bone.2015.08.012","journal-title":"Bone"},{"issue":"1","key":"6137_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30(1):3\u201323. https:\/\/doi.org\/10.1002\/jbmr.2405","journal-title":"J Bone Miner Res"},{"issue":"12","key":"6137_CR20","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00198-008-0660-9","volume":"19","author":"P Szulc","year":"2008","unstructured":"Szulc P, Delmas PD (2008) Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int 19(12):1683\u20131704. https:\/\/doi.org\/10.1007\/s00198-008-0660-9","journal-title":"Osteoporos Int"},{"issue":"3","key":"6137_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.critrevonc.2011.02.005","volume":"80","author":"R Coleman","year":"2011","unstructured":"Coleman R, Costa L, Saad F et al (2011) Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol 80(3):411\u2013432. https:\/\/doi.org\/10.1016\/j.critrevonc.2011.02.005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"6137_CR22","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","volume":"65","author":"RE Marx","year":"2007","unstructured":"Marx RE, Cillo JE, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65(12):2397\u20132410. https:\/\/doi.org\/10.1016\/j.joms.2007.08.003","journal-title":"J Oral Maxillofac Surg"},{"issue":"5","key":"6137_CR23","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/odi.13294","volume":"26","author":"O Nicolatou-Galitis","year":"2020","unstructured":"Nicolatou-Galitis O, Papadopoulou E, Vardas E et al (2020) Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. Oral Dis 26(5):955\u2013966. https:\/\/doi.org\/10.1111\/odi.13294","journal-title":"Oral Dis"},{"issue":"3","key":"6137_CR24","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/odi.13556","volume":"27","author":"O Ristow","year":"2021","unstructured":"Ristow O, Ruckschloss T, Moratin J et al (2021) Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-a randomized pilot trial. Oral Dis 27(3):532\u2013546. https:\/\/doi.org\/10.1111\/odi.13556","journal-title":"Oral Dis"},{"issue":"6","key":"6137_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","volume":"43","author":"S Otto","year":"2015","unstructured":"Otto S, Troltzsch M, Jambrovic V, Panya S, Probst F, Ristow O, Ehrenfeld M, Pautke C (2015) Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg 43(6):847\u2013854. https:\/\/doi.org\/10.1016\/j.jcms.2015.03.039","journal-title":"J Craniomaxillofac Surg"},{"issue":"8","key":"6137_CR26","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s00198-017-4063-7","volume":"28","author":"T Hasegawa","year":"2017","unstructured":"Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi M, Kondou E, Takeda D, Kojima Y, Sato SJOI (2017) A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? Osteoporosis Int 28(8):2465\u20132473","journal-title":"Osteoporosis Int"},{"issue":"9","key":"6137_CR27","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.joms.2010.05.043","volume":"68","author":"TS Lazarovici","year":"2010","unstructured":"Lazarovici TS, Mesilaty-Gross S, Vered I, Pariente C, Kanety H, Givol N, Yahalom R, Taicher S, Yarom N (2010) Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg 68(9):2241\u20132247. https:\/\/doi.org\/10.1016\/j.joms.2010.05.043","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"6137_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/ID.0b013e3181cec8bc","volume":"19","author":"CY Lee","year":"2010","unstructured":"Lee CY, Suzuki JB (2010) CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study. Implant Dentistry 19(1):29\u201338","journal-title":"Implant Dentistry"},{"issue":"1","key":"6137_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.bone.2003.04.002","volume":"34","author":"RA Hannon","year":"2004","unstructured":"Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A (2004) Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34(1):187\u2013194. https:\/\/doi.org\/10.1016\/j.bone.2003.04.002","journal-title":"Bone"},{"issue":"21\u201322","key":"6137_CR30","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.cca.2010.06.027","volume":"411","author":"TY Chao","year":"2010","unstructured":"Chao TY, Wu YY, Janckila AJ (2010) Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis. Clin Chim Acta 411(21\u201322):1553\u20131564. https:\/\/doi.org\/10.1016\/j.cca.2010.06.027","journal-title":"Clin Chim Acta"},{"issue":"9\u201310","key":"6137_CR31","first-page":"499","volume":"52","author":"JM Halleen","year":"2006","unstructured":"Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Vaananen HK (2006) Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 52(9\u201310):499\u2013509","journal-title":"Clin Lab"},{"issue":"6","key":"6137_CR32","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1210\/en.2007-0270","volume":"148","author":"R Baron","year":"2007","unstructured":"Baron R, Rawadi G (2007) Targeting the Wnt\/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148(6):2635\u20132643. https:\/\/doi.org\/10.1210\/en.2007-0270","journal-title":"Endocrinology"},{"issue":"12","key":"6137_CR33","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.1210\/jc.2005-2370","volume":"90","author":"SM Ott","year":"2005","unstructured":"Ott SM (2005) Sclerostin and Wnt signaling\u2013the pathway to bone strength. J Clin Endocrinol Metab 90(12):6741\u20136743. https:\/\/doi.org\/10.1210\/jc.2005-2370","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"6137_CR34","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1210\/er.2011-1060","volume":"33","author":"HZ Ke","year":"2012","unstructured":"Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33(5):747\u2013783. https:\/\/doi.org\/10.1210\/er.2011-1060","journal-title":"Endocr Rev"},{"issue":"3","key":"6137_CR35","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.bone.2011.11.028","volume":"50","author":"D Gatti","year":"2012","unstructured":"Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M (2012) Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50(3):739\u2013742. https:\/\/doi.org\/10.1016\/j.bone.2011.11.028","journal-title":"Bone"},{"issue":"10\u201311","key":"6137_CR36","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.clinbiochem.2009.04.007","volume":"42","author":"MJ Marshall","year":"2009","unstructured":"Marshall MJ, Evans SF, Sharp CA, Powell DE, McCarthy HS, Davie MW (2009) Increased circulating Dickkopf-1 in Paget\u2019s disease of bone. Clin Biochem 42(10\u201311):965\u2013969. https:\/\/doi.org\/10.1016\/j.clinbiochem.2009.04.007","journal-title":"Clin Biochem"},{"key":"6137_CR37","doi-asserted-by":"publisher","unstructured":"Ramli FF, Chin KY (2020) A review of the potential application of osteocyte-related biomarkers, fibroblast growth factor-23, sclerostin, and Dickkopf-1 in predicting osteoporosis and fractures. Diagnostics (Basel) 10(3). https:\/\/doi.org\/10.3390\/diagnostics10030145","DOI":"10.3390\/diagnostics10030145"},{"issue":"1","key":"6137_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jocd.2012.07.003","volume":"16","author":"AR Memon","year":"2013","unstructured":"Memon AR, Butler JS, O\u2019Riordan MV, Guerin E, Dimitrov BD, Harty JA (2013) Comparison of serum Dkk1 (Dickkopf-1) and bone mineral density in patients on bisphosphonate treatment vs no treatment. J Clin Densitom 16(1):118\u2013124. https:\/\/doi.org\/10.1016\/j.jocd.2012.07.003","journal-title":"J Clin Densitom"},{"issue":"8","key":"6137_CR39","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/jop.12031","volume":"42","author":"AC Vasconcelos","year":"2013","unstructured":"Vasconcelos AC, de Azambuja B-C, Figueiredo MA, Salum FG, Lopes TG, Cherubini K (2013) Laboratory methods and biomarkers in the evaluation of bisphosphonate effects on body tissues: a literature review. J Oral Pathol Med 42(8):577\u2013586. https:\/\/doi.org\/10.1111\/jop.12031","journal-title":"J Oral Pathol Med"},{"issue":"3","key":"6137_CR40","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","volume":"102","author":"E Terpos","year":"2003","unstructured":"Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A (2003) Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102(3):1064\u20131069. https:\/\/doi.org\/10.1182\/blood-2003-02-0380","journal-title":"Blood"},{"issue":"11","key":"6137_CR41","doi-asserted-by":"publisher","first-page":"6323","DOI":"10.1210\/jc.2005-0794","volume":"90","author":"A Rogers","year":"2005","unstructured":"Rogers A, Eastell R (2005) Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90(11):6323\u20136331. https:\/\/doi.org\/10.1210\/jc.2005-0794","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6137_CR42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/er.2007-0014","volume":"29","author":"AE Kearns","year":"2008","unstructured":"Kearns AE, Khosla S, Kostenuik PJ (2008) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29(2):155\u2013192. https:\/\/doi.org\/10.1210\/er.2007-0014","journal-title":"Endocr Rev"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06137-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-06137-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06137-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T08:04:03Z","timestamp":1643875443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-06137-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["6137"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-06137-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]},"assertion":[{"value":"29 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Bioethics Review Board of Ewha Womans University, Mokdong Hospital (IRB No. EUMC2018-01\u2013046-003).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}